- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04276038
Evaluation of the Efficacy of a Home-Use Photobiomodulation Device for the Treatment of Patients With Knee Osteoarthritis: A Prospective Double Blind, Randomized, Sham-Controlled Clinical Study
Osteoarthritis (OA) is a degenerative disease affecting joint cartilage and its surrounding tissue. It is the leading cause of disability in the elderly. The treatment of this disease remains limited to symptomatic relief and, ultimately, joint replacement. Despite the progress made in understanding the pathophysiology of OA, effective disease-modifying drugs are still lacking.
Low-level laser therapy (LLLT), also known as Photobiomodulation therapy, is a non-ionizing optical radiation in the visible or near infrared range of the spectrum. LLLI has been used widely for alleviation of pain, reduction of inflammation, and acceleration of wound healing. Specifically, it has been shown to reduce pain in chronic inflammatory related knee pathologies in pre-clinical and clinical studies. However, the recommended treatment protocol requires frequent treatments that translates to frequent visits at the clinic. Such a treatment regimen is difficult for Knee OA (KOA) patients and demanding of the clinical staff. Since the treatment itself can be self-applied easily, a home-use device would enable frequent treatments thereby improving patient adherence to the treatment.
In a pilot study, Kruglova et al [4] reported that 2 weeks of daily treatments with the home use B-Cure laser significantly reduced pain and increased flexibility in 20 elite athletes with KOA.
The purpose of the current study is to determine if B-Cure laser treatments, applied at home, by the patient or personal caregiver in a real-life situation, can reduce pain and improve functionality in patients with osteoarthritis of the knee.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Reut Wengier
- Phone Number: 972 36974720
- Email: reutw@tlvmc.gov.il
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnoses of knee osteoarthritis:( American College of Rheumatology (ACR) criteria (see below) - possibilities:ACR1: Fulfilled at least one of the classification criteria of the American College of Rheumatology ACR2: KOA verified with the American College of Rheumatology criteria using a history and physical examination, i.e. knee pain and at least three of the following: 50-85 years old, ≤ 30 minutes of morning stiffness, crepitus on active range of motion, bony tenderness, bony enlargement, and no palpable warmth of synovia Radiographic evidence of knee osteoarthritis between 2-3 in Kellgren and Lawrence classification
- KOA grade 2-3
- Knee pain on movement 40 to 90 mm Visual Analog Scale
- Knee pain for the last ≥ 3 months
- Functional reduction in the last three months
- Agrees not to use NSAIDs throughout the experiment
- Agrees not to use any other treatment (except rescue drugs) for KOA during participation in this study.
Exclusion Criteria:
- Other causes of knee-related pain (e.g. hip OA, arterial insufficiency, etc) have been ruled out by physical examinations
- Knee surgery for KOA
- Intra-articular steroid injection and/or oral steroid treatment within the last six months
- Rheumatoid arthritis;
- Symptomatic OA in other joints (i.e. hip, hand)
- Use of analgesics on the day of evaluation
- Use of NSAIDs 2 weeks before the beginning of the treatment
- Active malignancy
- Uncontrolled diabetes mellitus
- Neurological conditions: sciatica, neuropathy, multiple sclerosis
- Other chronic pain conditions: Fibromyalgia, back pain, hip pain
- Enrolled in any other clinical trial within the last 6 weeks or enrollment in another clinical trial during participation in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active LLLT
Patients will self-treat at home (active or sham), twice a day (excluding Weekends) for 1 month. The duration of each session will be 15-20 minutes and will include treatment over painful point on the knee and over regional lymph nodes (popliteal, inguinal). The treatment dose should be initiated gradually for the first week until reaching the maximum dose of 6-8 minutes per treatment point. This is the recommended dose for near infrared lasers for the indication of knee pain by the World Association for Laser Therapy (WALT). In the first days an increase in pain may be felt before the reduction in pain. If the increase in pain continues for more than a week under graded dosimetry, the treatment must be stopped. Laser therapy will be administered to the patients in addition to standard of care therapy as customary in our institution. |
The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
The device is used at home and is self-applied by the patient.
The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment.
The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
|
Sham Comparator: Sham LLLT
Half of the LLT devices will be not activated at random before the application to the patients.
Sham activated devices will give outward signs of normal function but will not generate a signal.
The investigators will be unaware of the device's functionality.
The patients will not be able to determine whether the device is working or not.
At study completion, device serial numbers will be used to determine which patients received a working device.
|
The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
The device is used at home and is self-applied by the patient.
The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment.
The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the effectiveness of B-cure laser for pain reduction in patients with knee osteoarthritis
Time Frame: time point - 1 month
|
Change from baseline in pain score by visual analog scale (VAS), 0-10, 0 - no pain; 10- worst pain
|
time point - 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Range of Movement
Time Frame: time point - 1 month
|
Change from baseline
|
time point - 1 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0438-19-TLV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Tianjin XinChen-Techfields Pharma Co., LTD.Completed
-
Eun Jung KimMinistry of Health & Welfare, Korea; Semyung UniversityUnknownOsteoarthritis KneeKorea, Republic of
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
Clinical Trials on B-Cure laser pro
-
Erika Carmel ltdNot yet recruitingDiabetic Foot UlcerIsrael
-
Scarborough Rouge HospitalRecruitingDiabetic Foot UlcerCanada
-
Erika Carmel ltdNot yet recruiting
-
Erika Carmel ltdRecruitingHead and Neck Cancer | Mucositis | Radiotherapy Side EffectIsrael
-
Erika Carmel ltdTel-Aviv Sourasky Medical CenterRecruitingDiabetic Foot UlcerIsrael
-
Erika Carmel ltdHoly Family Hospital, Methuen, MACompletedRotator Cuff TearsIsrael
-
Hillel Yaffe Medical CenterUnknown
-
Erika Carmel ltdHoly Family Hospital, Nazareth, IsraelRecruiting
-
Hadassah Medical OrganizationUnknownDiabetic Foot UlcerIsrael
-
The University of Texas Medical Branch, GalvestonCompletedDiet | Protein | Skeletal MuscleUnited States